Biogen   3Q Revenues: $3.0 billion (+6%) 3Q Earnings: $1.0 billion (+1%) YTD Revenues: $8.6 billion (+8%) YTD Earnings: $3.0 billion (+10%) Comments: Growth in the quarter was driven by a 10% increase in TECFIDERA revenues to $1.0 billion, as well as increased TYSABRI sales, up 7% to $515 million, ELOCTATE sales, up 46% to $132 million, ALPROLIX sales, up 30% to $85 million, and the launch of biosimilar products BENEPALI and FLIXABI in Europe. Biosimilar revenues were $31 million i...